en · de · es
melanotan-2-notes.peptides3081.com › Topic › Chemistry And Receptor Pharmacology — What the Evidence Shows

Chemistry And Receptor Pharmacology — What the Evidence Shows

By Editorial Desk · published 2025-12-26 · last reviewed 2026-01-24 · Topic

The short version of cyclic heptapeptide fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-01-24. Anything still debated is marked as such rather than presented as settled.

Chemistry and Receptor Pharmacology

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Regulation, Literature and Verification

Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.

Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.

Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Cyclic heptapeptide, C-terminally amidated
Approximate molecular mass1024 DaMonoisotopic mass of the free peptide
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
Solubility classSoluble in water and polar solventsAlso dissolves in neutral aqueous buffer
Common synonymsMelanotan II, MT-II, MT-2Described as a melanocortin agonist in early literature

Background and Receptor Mechanism

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.

Related pages on this site

Handling, Storage, and Analytical Verification

Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.

Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.

Melanotan-2 Identity and Receptor Pharmacology

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Storage, Verification and Regulatory Status

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.

Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.

Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.

Background from the literature

=== Changes in menus === To make MREs more palatable to service members and match ever-changing trends in popular tastes, the military is constantly seeking feedback to adjust MRE menus and ingredients. In the following list, only main entrees are listed. Vegetarian menus are marked and footnoted on their first appearance.

=== EC 2.4.99: Transferring Other Glycosyl Groups === EC 2.4.99.1: β-galactoside α-(2,6)-sialyltransferase EC 2.4.99.2: β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminide α-2,3-sialyltransferase EC 2.4.99.3: α-N-acetylgalactosaminide α-2,6-sialyltransferase EC 2.4.99.4: β-galactoside α-2,3-sialyltransferase EC 2.4.99.5: galactosyldiacylglycerol α-2,3-sialyltransferase EC 2.4.99.6: N-acetyllactosaminide α-2,3-sialyltransferase EC 2.4.99.7: α-N-acetylneuraminyl-2,3-β-galactosyl-1,3-N-acetylgalactosaminide 6-α-sialyltransferase EC 2.4.99.8: α-N-acetylneuraminate α-2,8-sialyltransferase EC 2.4.99.9: lactosylceramide α-2,3-sialyltransferase EC 2.4.99.10: Now included in EC 2.4.99.6, N-acetyllactosaminide α-2,3-sialyltransferase EC 2.4.99.11: Now included with EC 2.4.99.1,β-galactoside α-(2,6)-sialyltransferase EC 2.4.99.12: lipid IVA 3-deoxy-D-manno-octulosonic acid transferase EC 2.4.99.13: (Kdo)-lipid IVA3-deoxy-D-manno-octulosonic acid transferase EC 2.4.99.14: (Kdo)2-lipid IVA (2-8) 3-deoxy-D-manno-octulosonic acid transferase EC 2.4.99.15: (Kdo)3-lipid IVA (2-4) 3-deoxy-D-manno-octulosonic acid transferase EC 2.4.99.16: starch synthase (maltosyl-transferring) EC 2.4.99.17: S-adenosylmethionine:tRNA ribosyltransferase-isomerase EC 2.4.99.18: dolichyl-diphosphooligosaccharide—protein glycotransferase EC 2.4.99.19: undecaprenyl-diphosphooligosaccharide—protein glycotransferase EC 2.4.99.20: 2′-phospho-ADP-ribosyl cyclase/2′-phospho-cyclic-ADP-ribose transferase EC 2.4.99.21: dolichyl-phosphooligosaccharide-protein glycotransferase EC 2.4.99.22: N-acetylglucosaminide α-(2,6)-sialyltransferase

=== Cap snatching in Hantaviridae === Cap snatching has also been investigated in depth for the family Hantaviridae (Bunyavirales). There is evidence that the N protein binds to the 5' cap and protects them from degradation by cellular machinery. The N protein accumulates in cytoplasmic cellular processing bodies (P bodies), sequestering the protected 5' caps as a pool of available primers for the RdRp to begin viral mRNA synthesis. There are four nucleotides on the vRNA that are adjacent the 5' cap for binding. The virus preferentially cleaves mRNA cap at a G residue 14 nucleotides downstream from the cap. Additionally, it usually cleaves caps from nonsense mRNA instead of actively translated mRNA. The N protein can guard host mRNA caps without P-bodies, but they are not used as efficiently by the RdRp. The Hantaviridae RdRp can also engage in a "prime and realign" mechanism: The host oligonucleotide primes mRNA transcription and initiates transcription with a terminal G residue. After several nucleotides are added, the nascent RNA realigns by moving two nucleotides backwards on the repeated terminal sequence (AUCAUCAUC) so that the host G is once again the first nucleotide, creating a 5' end extension.

In 2014, Guinness released Guinness Blonde, a lager brewed in Latrobe, Pennsylvania using a combination of Guinness yeast and American ingredients. When Guinness opened their new brewery in Baltimore, Maryland in August 2018 they recreated "Blonde" to "Baltimore Blonde" by adjusting the grain mixture and adding Citra for a citrus flavour and removed the Mosaic hops. Guinness released a lager in 2015 called Hop House 13. It was withdrawn from sale in the UK in May 2021, following poor sales, but remains on sale in Ireland. In 2020, Guinness announced the introduction of a zero alcohol canned stout, Guinness 0.0. It was withdrawn from sale almost immediately after launch, due to contamination. It was relaunched in 2021 starting with pubs in mid July with cans following in late August. In September 2021, Guinness Nitrosurge was released in pint sized cans which contain no widget. Similar to the Surger, nitrogen is activated using ultrasonic frequencies. Nitrosurge uses a special device attached to the top of the can which activates the nitrogen as it is being poured.

Iran dismisses a peace plan proposed by the U.S., calling the demands "excessive". The White House warns Iran that Donald Trump will "ensure they are hit harder than ever before" if the country refuses to accept defeat. The U.S. Supreme Court unanimously holds that internet service providers are not liable for the copyright infringement of their users if the ISP did not intend its services to be used for infringement. Trump signs an executive order requiring proof of U.S. citizenship for voter registration.

Sources: en.wikipedia.org

Reference notes

Argon is used in the poultry industry to asphyxiate birds, either for mass culling following disease outbreaks, or as a means of slaughter more humane than electric stunning. Argon is denser than air and displaces oxygen close to the ground during inert gas asphyxiation. Its non-reactive nature makes it suitable in a food product, and since it replaces oxygen within the dead bird, argon also enhances shelf life. Argon is sometimes used for extinguishing fires where valuable equipment may be damaged by water or foam.

Natriuretic peptide precursor C, also known as NPPC, is a protein that in humans is encoded by the NPPC gene. The precursor NPPC protein is cleaved to the 22 amino acid peptide C-type natriuretic peptide (CNP).

=== Andy: Get The Poison Out === First aired: 4 November 2010 Meet Andy, the self-appointed king of Fresno. He is an obnoxious bully who makes life miserable for his victims, Steven and Taylor. He also makes the biggest mistake of calling out Mayhem, so Mayhem brings out "the greatest fighter he has ever known" to take care of Andy. That fighter turns out to be Mayhem himself. After easily being tapped out 5 times in the first round and knocked out in the second round, Steven and Taylor won $10,000. After the fight, Mayhem tells a humbled Andy that he had to deal with bullies most of his life and implores him to change his ways because he eventually will come across someone that is bigger, badder and meaner than Andy himself.

== In popular culture == Grogu sipping bone broth in "Chapter 4: Sanctuary" (2019), the fourth episode of the first season of the American streaming television series The Mandalorian, became an Internet meme, as the cuteness of the character's slurping made two other characters abruptly stop fighting.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II identical to alpha-melanocyte-stimulating hormone?

No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.

How does melanotan II differ from afamelanotide?

Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.

Is the receptor binding profile well established?

Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.

Has it been tested in clinical trials?

Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.

Network